These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11221955)

  • 1. Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia.
    Bellott R; Auvrignon A; Leblanc T; Pérel Y; Gandemer V; Bertrand Y; Méchinaud F; Bellenger P; Vernois J; Leverger G; Baruchel A; Robert J
    Cancer Chemother Pharmacol; 2001; 47(1):15-21. PubMed ID: 11221955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma.
    Fumagalli L; Zucchetti M; Parisi I; Viganò MG; Zecca B; Careddu A; D'Incalci M; Lazzarin A
    Cancer Chemother Pharmacol; 2000; 45(6):495-501. PubMed ID: 10854138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
    Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
    Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia.
    Pea F; Russo D; Michieli M; Baraldo M; Ermacora A; Damiani D; Baccarani M; Furlanut M
    Cancer Chemother Pharmacol; 2000; 46(4):279-86. PubMed ID: 11052625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol.
    Hempel G; Relling MV; de Rossi G; Stary J; De Lorenzo P; Valsecchi MG; Barisone E; Boos J; Pieters R
    Pediatr Blood Cancer; 2010 Mar; 54(3):355-60. PubMed ID: 19731319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
    Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
    J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin.
    Zucchetti M; Boiardi A; Silvani A; Parisi I; Piccolrovazzi S; D'Incalci M
    Cancer Chemother Pharmacol; 1999; 44(2):173-6. PubMed ID: 10412954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of liposomal daunorubicin in children.
    Hempel G; Reinhardt D; Creutzig U; Boos J
    Br J Clin Pharmacol; 2003 Oct; 56(4):370-7. PubMed ID: 12968981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.
    Pea F; Russo D; Michieli M; Damiani D; Fanin R; Michelutti A; Michelutti T; Piccolrovazzi S; Baccarani M; Furlanut M
    Clin Pharmacokinet; 2003; 42(9):851-62. PubMed ID: 12882589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immobilized forms of daunorubicin in patients with acute leukemia].
    Isaev VG; Garmaeva TTs; Skorokhod AA; Parovichnikova EN; Tiurina NG; Kucher RA; Vitvitskiĭ VM; Ataullakhanov FI; Savchenko VG
    Ter Arkh; 1999; 71(10):32-7. PubMed ID: 10612171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes.
    Yeo W; Chan KK; Mukwaya G; Ross M; Leung WT; Ho S; Chan AT; Johnson PJ
    Cancer Chemother Pharmacol; 1999; 44(2):124-30. PubMed ID: 10412946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome.
    Bellott R; Pouna P; Robert J
    J Chromatogr B Biomed Sci Appl; 2001 Jun; 757(2):257-67. PubMed ID: 11417870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
    Fassas A; Buffels R; Anagnostopoulos A; Gacos E; Vadikolia C; Haloudis P; Kaloyannidis P
    Br J Haematol; 2002 Feb; 116(2):308-15. PubMed ID: 11841431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979).
    Callies S; de Alwis DP; Mehta A; Burgess M; Aarons L
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):39-48. PubMed ID: 15045528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat.
    Cusack BJ; Young SP; Vestal RE; Olson RD
    Cancer Chemother Pharmacol; 1997; 39(6):505-12. PubMed ID: 9118462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of free and liposome-associated daunorubicin and daunorubicinol in plasma by capillary electrophoresis.
    Griese N; Blaschke G; Boos J; Hempel G
    J Chromatogr A; 2002 Dec; 979(1-2):379-88. PubMed ID: 12498269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia.
    Russo D; Piccaluga PP; Michieli M; Michelutti T; Visani G; Gugliotta L; Bonini A; Pierri I; Gobbi M; Tiribelli M; Fanin R; Piccolrovazzi S; Baccarani M
    Ann Hematol; 2002 Aug; 81(8):462-6. PubMed ID: 12224004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients.
    Robert J; Rigal-Huguet F; Hurteloup P
    Hematol Oncol; 1992; 10(2):111-6. PubMed ID: 1592361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia.
    Galettis P; Boutagy J; Ma DD
    Br J Cancer; 1994 Aug; 70(2):324-9. PubMed ID: 7914424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.